VIP PC Cinemas announces permanent closure in June

PANAMA CITY, Fla. (WMBB) – VIP PC Cinemas at the Panama City Mall has announced that on June 15, 2025, its doors will permanently close.
According to a VIP PC Cinemas Facebook post, 'We want to thank our loyal guests for all the years of support as we have (quite literally) weathered storms and adapted to a changing landscape at the Panama City Mall. This is the end of an unforgettable chapter for this theater, but the memories made here will live on forever. We hope you'll join us between now and the 15th for our final nights of movies, memories, and gratitude as we say goodbye.'
All 2025 VIP Bucket holders and their party will be eligible to receive a $5 discount on admission to any regularly scheduled show until its final day of operation. Additionally, all refills on its 2025 VIP Bucket will be free until its final day of operation.
VIP PC Cinemas said that any guests with gift cards that have an unused balance will be refunded upon request.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Upturn

24 minutes ago

• Business Upturn

Fujirebio Acquires Plasma Services Group and Strengthens Its Position as Provider of Critical and High Quality Biological Raw Materials to the IVD and Life Science Industries

By Business Wire India Published on June 23, 2025, 16:23 IST TOKYO, Japan & MALVERN, Pa., United States: H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter 'Fujirebio') today announced that Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio, has acquired all shares of Plasma Services Group, Inc. (hereinafter 'Plasma Services Group'). The transaction value has not been disclosed. Founded in 2004, Plasma Services Group has specialized in the collection, screening and supply of high quality and rare biological materials required for R&D and manufacturing in the in vitro diagnostics (IVD) and life science industries. The company is particularly well positioned in the field of rare diseases. From its state-of-the-art FDA registered, ISO certified facility in Moorestown, NJ, USA, Plasma Services Group provides sera and other samples for materials of control reagents and calibrators for a wide range of diseases and offers sample collection services globally. For more information about Plasma Services Group please visit 'We are excited to welcome Plasma Services Group, a company that has gained a solid reputation as a reliable global supplier of difficult-to-obtain biological raw materials to the life sciences industry, to the Fujirebio group of companies,' says Goki Ishikawa, President & CEO of Fujirebio Holdings, Inc. 'Current and future IVD and life science partners of Fujirebio and Plasma Services Group will benefit from the synergies in our combined offer of rare samples and biological materials, which in turn further reinforce Fujirebio's position in the market as a trusted CDMO partner.' 'For over 20 years our mission at PSG has always been rooted in serving our customers with care, integrity, and a commitment to quality,' said Nichelle Fernandez, President of Plasma Services Group. 'This next chapter with Fujirebio is deeply meaningful. It allows us to stay true to who we are while preserving the personal, responsive service our customers value. Together, we're positioned to offer even stronger support for the scientists and innovators who rely on us. Our shared commitment to consistency will have a lasting impact across the global IVD landscape.' Advisors Houlihan Lokey acted as exclusive financial advisor to Fujirebio. Achelous Partners acted as exclusive financial advisor to Plasma Services Group. About Fujirebio Fujirebio is global R&D-driven company constantly developing new IVD testing technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical global teams located in Japan, Asia, Europe, and the US focus on delivering products with the highest quality standards to our customers and partners. We value CDMO partnerships with many of the world's leading diagnostic companies, sharing knowledge, capabilities, and critical materials to supply, develop, or manufacture diagnostic solutions on a wide variety of more information about Fujirebio, please visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.

San Francisco Chronicle​

an hour ago

• San Francisco Chronicle​

Jerash: Fiscal Q4 Earnings Snapshot

FAIRFIELD, N.J. (AP) — FAIRFIELD, N.J. (AP) — Jerash Holdings (US), Inc. (JRSH) on Monday reported a loss of $153,000 in its fiscal fourth quarter. The Fairfield, New Jersey-based company said it had a loss of 1 cent per share. The company posted revenue of $29.3 million in the period. For the current quarter ending in June, Jerash said it expects revenue in the range of $38 million to $40 million. _____

Business Wire

an hour ago

• Business Wire

Ancora Heart Inc. Reaches First Enrollment Milestone in CORCINCH-HF Heart Failure Pivotal Trial

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Ancora Heart, Inc., a medical device company developing a transcatheter device-based therapy to address heart failure (HF), today announced that it has reached the first enrollment milestone in the CORCINCH-HF pivotal trial evaluating the AccuCinch ® Transcatheter Left Ventricular Restoration System in patients with heart failure with reduced ejection fraction (HFrEF). Six-month follow-up data on these 250 patients will support the company's Premarket Approval (PMA) submission to the U.S. Food and Drug Administration (FDA). 'The AccuCinch System is the only completely transcatheter procedure to treat the enlarged left ventricle. Reaching this milestone is an incredible accomplishment in heart failure research." - Jeff Closs, president and CEO, Ancora Heart Share The AccuCinch System is an investigational device designed to reduce the size of the left ventricle, reduce ventricular wall stress, and support and strengthen the heart wall. Results from early clinical studies were presented at the 2023 Technology and Heart Failure Therapeutics conference and simultaneously published in the Journal of Cardiac Failure. The AccuCinch System was granted Breakthrough Device Designation from the FDA in 2022. 'The AccuCinch System is the only completely transcatheter procedure to treat the enlarged left ventricle,' said Jeff Closs, president and CEO of Ancora Heart. 'Reaching this milestone is an incredible accomplishment in heart failure research and a model example of collaboration across heart failure and structural heart care teams at participating CORCINCH-HF clinical trial sites. We'd like to thank study investigators for their commitment to innovation and partnership, and we look forward to building on this momentum as we work toward reaching our full enrollment target of 400 patients.' The CORCINCH-HF study is evaluating the safety and effectiveness of the AccuCinch System in patients who have symptomatic HF with reduced ejection fraction. An estimated 6.7 million adults in the U.S. live with heart failure, and about half have HFrEF. 1,2 'Despite advances in guideline-directed medical therapy, many patients with heart failure continue to experience debilitating symptoms,' said Ulrich Jorde, MD, global co-principal investigator of the CORCINCH-HF Study, professor of medicine, Albert Einstein College of Medicine, and section head of Heart Failure, Cardiac Transplantation and Mechanical Circulatory Support at Montefiore Health System in New York. 'Reaching this milestone in the CORCINCH-HF study is a significant step toward determining whether this treatment option may improve the length and quality of their lives.' 'AccuCinch is a device-based therapy aimed at reverse remodeling of the enlarged left ventricle,' said Mark Reisman, MD*, global co-principal investigator of the CORCINCH-HF Study, director of structural heart disease at NewYork-Presbyterian/Weill Cornell Medical Center and co-director of structural heart disease for NewYork-Presbyterian Queens and NewYork-Presbyterian Brooklyn Methodist Hospital, who was recruited to Weill Cornell Medicine as a professor of medicine. 'This trial is designed to evaluate the safety of the device and procedure and whether we can improve heart structure and function and thereby help patients feel better, avoid hospitalizations and live longer.' About Heart Failure An estimated 6.7 million adults in the U.S. live with heart failure, a condition in which the heart's muscles weaken and lose their ability to pump enough oxygen-rich blood to the body. 1,2 Heart failure patients suffer from debilitating symptoms, including persistent exhaustion, trouble breathing and confusion, as well as frequent hospitalizations. About half of HF patients have heart failure with a reduced ejection fraction (HFrEF) and an enlarged left ventricle, the main pumping chamber of the heart, which causes more stress on the heart and leads to reduced pumping efficiency. Up to 50% of people who develop heart failure die within five years of diagnosis. 3 About the AccuCinch ® Transcatheter Left Ventricular Restoration System The AccuCinch System is an investigational device designed to augment the existing care cardiologists provide their heart failure patients. For patients in whom HF has progressed beyond the ability of medications and pacemakers to manage symptoms, the AccuCinch System may provide a new treatment option to fill the gap between medication or pacemaker therapy and left ventricular assist devices (LVADs) or a heart transplant. During the minimally invasive AccuCinch System procedure, a flexible implant is attached to the inner wall of the left ventricle and then cinched. The implant is intended to reduce the size of the left ventricle, reduce ventricular wall stress, and support and strengthen the heart wall. The AccuCinch System is under clinical evaluation to determine its potential benefits related to patient symptoms, quality of life and life expectancy. About the CORCINCH-HF Study The CORCINCH-HF Study (NCT04331769) is a prospective, randomized, open-label, multicenter, international, clinical safety and effectiveness investigation of the AccuCinch Transcatheter Left Ventricular Restoration System, which is designed to enroll 400 patients at centers worldwide. The study has a unique design allowing initial analysis of safety and clinical effectiveness for PMA submission after the first 250 patients have reached six months of follow-up, and then a second analysis after the entire cohort has reached 12 months of follow-up. About Ancora Heart, Inc. Ancora Heart is a medical device company dedicated to providing new treatment options for people with heart failure (HF). The company's lead product is the AccuCinch ® Transcatheter Left Ventricular Restoration System, an investigational device currently being studied in the CORCINCH-HF pivotal trial. Ancora Heart is a privately held company located in Santa Clara, Calif. For more information, about Ancora Heart and its products, visit and follow the company on Facebook, LinkedIn and X. * Dr. Reisman reports travel support from Ancora Heart. 1 Martin SS, Aday AW, Almarzooq ZI, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee; Stroke Statistics Subcommittee. 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2024;149:e347–913. 2 Murphy S, Ibrahim N, Januzzi J. Heart Failure with Reduced Ejection Fraction, A Review. JAMA. 2020;324(5):488-504 3 Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139-596.